Hospira Drug Shortage Suit Must Be Revived, 11th Circ. Told

Law360, Washington (January 4, 2013, 8:03 PM EST) -- A putative class of individuals affected by Hospira Inc.'s decision to stop producing an injectable vitamin supplement on Thursday urged the Eleventh Circuit to revive their suit, alleging other companies may stop producing life-saving drugs if they don't face the threat of similar litigation.

In July, a Florida federal judge tossed the complaint over shortages of the vitamin A medicine called Aquasol A with prejudice, determining it would improperly intrude on Hospira's business prerogatives. But the plaintiffs told the appeals court they should have been allowed to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.